Scalper1 News
Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with hepatitis C genotype 1 who took a combination of its drug candidates MK-5172 and MK-8742. With the two combined in one pill taken once per day, the pairing rivals the convenience and effectiveness of Scalper1 News
Scalper1 News